REPORTS

Let’s Pullulate and Expand Your Business

Drug, Anti-infective Market - Global Professional Analysis and Forecast to 2026

Jan 05, 2020  |  153 PAGES  |  REPORT CODE: CMM259807
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Drug, Anti-infective market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.9% during the forecast period.

This report presents the market size and development trends by detailing the Drug, Anti-infective market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Drug, Anti-infective market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Drug, Anti-infective industry and will help you to build a panoramic view of the industrial development.

Drug, Anti-infective Market, By Type:

  • OTC

  • Rx Drugs

Drug, Anti-infective Market, By Application:

  • Hospital

  • Drugs Store

  • Other

Some of the leading players are as follows:

  • Wyeth

  • Novabay Pharmaceuticals

  • NanoViricides

  • Abbott

  • Gilead Sciences

  • Johnson

  • Sanofi-Aventis

  • Nanosphere

  • Basilea Pharmaceutica AG

  • Roche Pharma AG

  • Theravance

  • GlaxoSmithKline

  • Daiichi Sankyo

  • Optimer Pharmaceuticals

  • Pfizer

  • Bristol-Myers Squibb

  • MerLion Pharma

  • Obetech

  • Merck

  • Novartis AG

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Drug, Anti-infective Market: Technology Type Analysis

  • 4.1 Drug, Anti-infective Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Drug, Anti-infective Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 OTC

    • 4.3.2 Rx Drugs

5 Drug, Anti-infective Market: Product Analysis

  • 5.1 Drug, Anti-infective Product Market Share Analysis, 2018 & 2026

  • 5.2 Drug, Anti-infective Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Drug, Anti-infective Market: Application Analysis

  • 6.1 Drug, Anti-infective Application Market Share Analysis, 2018 & 2026

  • 6.2 Drug, Anti-infective Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Hospital

    • 6.3.2 Drugs Store

    • 6.3.3 Other

7 Drug, Anti-infective Market: Regional Analysis

  • 7.1 Drug, Anti-infective Regional Market Share Analysis, 2018 & 2026

  • 7.2 Drug, Anti-infective Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Wyeth

    • 9.1.1 Wyeth Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Novabay Pharmaceuticals

    • 9.2.1 Novabay Pharmaceuticals Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 NanoViricides

    • 9.3.1 NanoViricides Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Abbott

    • 9.4.1 Abbott Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Gilead Sciences

    • 9.5.1 Gilead Sciences Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Johnson

    • 9.6.1 Johnson Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Sanofi-Aventis

    • 9.7.1 Sanofi-Aventis Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Nanosphere

    • 9.8.1 Nanosphere Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Basilea Pharmaceutica AG

    • 9.9.1 Basilea Pharmaceutica AG Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Roche Pharma AG

    • 9.10.1 Roche Pharma AG Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Theravance

    • 9.11.1 Theravance Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 GlaxoSmithKline

    • 9.12.1 GlaxoSmithKline Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 Daiichi Sankyo

    • 9.13.1 Daiichi Sankyo Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 Optimer Pharmaceuticals

    • 9.14.1 Optimer Pharmaceuticals Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 Pfizer

    • 9.15.1 Pfizer Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

  • 9.16 Bristol-Myers Squibb

    • 9.16.1 Bristol-Myers Squibb Company overview

    • 9.16.2 Financial performance

    • 9.16.3 Product benchmarking

    • 9.16.4 Strategic initiatives

    • 9.16.5 SWOT analysis

  • 9.17 MerLion Pharma

    • 9.17.1 MerLion Pharma Company overview

    • 9.17.2 Financial performance

    • 9.17.3 Product benchmarking

    • 9.17.4 Strategic initiatives

    • 9.17.5 SWOT analysis

  • 9.18 Obetech

    • 9.18.1 Obetech Company overview

    • 9.18.2 Financial performance

    • 9.18.3 Product benchmarking

    • 9.18.4 Strategic initiatives

    • 9.18.5 SWOT analysis

  • 9.19 Merck

    • 9.19.1 Merck Company overview

    • 9.19.2 Financial performance

    • 9.19.3 Product benchmarking

    • 9.19.4 Strategic initiatives

    • 9.19.5 SWOT analysis

  • 9.20 Novartis AG

    • 9.20.1 Novartis AG Company overview

    • 9.20.2 Financial performance

    • 9.20.3 Product benchmarking

    • 9.20.4 Strategic initiatives

    • 9.20.5 SWOT analysis

 

The List of Tables and Figures (Totals 74 Figures and 156 Tables)

  • Figure OTC Drug, Anti-infective market, 2015 - 2026 (USD Million)

  • Figure Rx Drugs Drug, Anti-infective market, 2015 - 2026 (USD Million)

  • Figure Hospital market, 2015 - 2026 (USD Million)

  • Figure Drugs Store market, 2015 - 2026 (USD Million)

  • Figure Other market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Drug, Anti-infective market, by country, 2015 - 2026 (USD Million)

  • Table North America Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table North America Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table North America Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table Canada Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table Canada Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Europe Drug, Anti-infective market, by country, 2015 - 2026 (USD Million)

  • Table Europe Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table Europe Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table Europe Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table Germany Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table Germany Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table France Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table France Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table Italy Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table Italy Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table Spain Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table Spain Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Drug, Anti-infective market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table China Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table China Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table Japan Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table Japan Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table India Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table India Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Drug, Anti-infective market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table MEA Drug, Anti-infective market, by country, 2015 - 2026 (USD Million)

  • Table MEA Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table MEA Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table MEA Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Drug, Anti-infective market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Drug, Anti-infective market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Drug, Anti-infective market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Wyeth Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novabay Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table NanoViricides Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Abbott Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Gilead Sciences Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Johnson Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sanofi-Aventis Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Nanosphere Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Basilea Pharmaceutica AG Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Roche Pharma AG Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Theravance Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table GlaxoSmithKline Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Daiichi Sankyo Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Optimer Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table MerLion Pharma Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Obetech Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Merck Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novartis AG Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top